The estimated Net Worth of Gregory W Schafer is at least 1.33 百万$ dollars as of 25 January 2018. Gregory Schafer owns over 60,000 units of Cerus stock worth over 514,027$ and over the last 21 years Gregory sold CERS stock worth over 813,373$.
Gregory has made over 19 trades of the Cerus stock since 2015, according to the Form 4 filled with the SEC. Most recently Gregory exercised 60,000 units of CERS stock worth 49,200$ on 25 January 2018.
The largest trade Gregory's ever made was exercising 80,000 units of Cerus stock on 10 November 2016 worth over 116,000$. On average, Gregory trades about 18,911 units every 25 days since 2003. As of 25 January 2018 Gregory still owns at least 250,745 units of Cerus stock.
You can see the complete history of Gregory Schafer stock trades at the bottom of the page.
Gregory's mailing address filed with the SEC is C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: